news.google.com· FierceBiotech·· 2 days agoPickScore58
Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals - Fierce Biotech
In brief
Fierce Biotech reports that the U.S. Treasury's proposed COINS Act restrictions would sweep biotech into outbound investment controls on China, while exempting Big Pharma's China licensing deals. The headline is the story; details await full disclosure.
Why it matters
Shows how proposed rules treat biotech investment differently from Big Pharma licensing deals for China compliance planning.
Source: news.google.com · news.google.com